Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 12 January 2026 - 13 January 2026

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares rose 1.6% to $212.98 Tuesday, outperforming a dip in healthcare stocks. Delaware’s Supreme Court ordered a recalculation of part of a $1 billion damages award tied to the Auris acquisition, which could reduce the payout by hundreds of millions. Legal developments and upcoming drug trial data are in focus ahead of the company’s Jan. 21 earnings call.
13 January 2026
···
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly shares rose 0.2% after the FDA asked drugmakers to remove suicide-related warnings from GLP-1 weight-loss drugs. Lilly’s R&D chief said the company plans a rapid global launch of its oral obesity drug orforglipron, priced at $150 a month. Investors are watching for increased pill competition and the FDA’s upcoming decision.
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck raised its long-term revenue forecast for new products to $70 billion by the mid-2030s, lifting its cardiometabolic and respiratory outlook to $20 billion and infectious disease to $15 billion. Shares fell 1.2% to $109.19. Johnson & Johnson rose 2.6%, Eli Lilly gained 1.6%, and Pfizer slipped 0.8%. Merck said its pipeline could offset Keytruda’s loss of exclusivity by 2026.
13 January 2026
··
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer shares fell 0.8% to $25.27 after CEO Albert Bourla compared the obesity drug cash-pay market to Viagra’s early days. The company, which acquired Metsera for up to $10 billion, aims to start up to 10 Phase 3 trials for Metsera’s GLP-1 drug by end-2026. Eli Lilly and Novo Nordisk shares rose, while Pfizer trails rivals in the obesity market.
13 January 2026
···
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam shares fell 6.7% to $370.91 after preliminary fourth-quarter sales for Amvuttra missed Wall Street estimates. The company reported about $827 million in Amvuttra revenue, below analyst expectations of $852 million. Alnylam set 2026 product revenue guidance at $4.9 billion to $5.3 billion and outlined a new five-year plan. Full results are due in February.
13 January 2026
···
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
12 January 2026
···
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Recursion Pharmaceuticals shares rose 4.4% to $4.87 Monday after an updated investor presentation showed $755 million in cash at year-end 2025 and a projected runway through 2027. The company reported a 43% median reduction in polyp burden for its lead drug REC-4881 in a small trial, with mostly mild to moderate side effects. Recursion will present at the J.P. Morgan Healthcare Conference Tuesday.
12 January 2026
··
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines shares fell 1.8% to $116.51 in early Monday trading, retreating from last week’s highs after reports of ongoing Merck acquisition talks valuing the company at up to $32 billion. Truist maintained its Buy rating but kept its price target at $99, below the current price. Investors await the company’s presentation at the J.P. Morgan Healthcare Conference later Monday.
12 January 2026
··
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva shares rose about 4% to $33.29 after announcing a funding deal with Royalty Pharma worth up to $500 million for its experimental vitiligo drug. An SEC filing previewed Teva’s 2025 outlook, including projected revenue of $16.8–$17.0 billion and adjusted EBITDA of $4.8–$5.0 billion. Investors await more details at Tuesday’s J.P. Morgan Healthcare Conference.
12 January 2026
··
NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals shares fell 10% to $17.21 in premarket trading Monday, following a 102.5% surge Friday on unusually heavy volume. Traders are watching for updates on warrants and share supply after the company disclosed possible new share issuances and a reverse split. NovaBay has not commented on the recent volatility. Fourth-quarter results are expected March 25.
12 January 2026
··
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
1 … 9 10 11 12 13 … 34

Stock Market Today

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

7 February 2026
New York, February 7, 2026, 13:20 EST — Market closed U.S. financial services stocks finished the week firmer, with the Financial Select Sector SPDR Fund (XLF) — an exchange-traded fund tracking financial shares — up 1.8% to $54.26 at Friday’s close. Goldman Sachs gained 4.3%, JPMorgan Chase rose 3.9% and Citigroup added 6.0%. The move capped a broad Wall Street rebound that pushed the Dow Jones Industrial Average to a first close above 50,000 on Friday, up 2.47% on the day, as money spread out beyond technology after an AI-related selloff earlier in the week. Chuck Carlson, chief executive of
Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

7 February 2026
Digital Realty, Equinix, and Vertiv shares surged Friday, with Vertiv up 10% and Digital Realty rising 4.1%, as investors rotated back into AI-linked data center stocks. The move followed Amazon’s $200 billion and Alphabet’s $175–185 billion 2026 capex targets. Digital Realty set 2026 core FFO guidance at $7.90 to $8.00 per share. Wall Street ended the week broadly higher, led by chipmakers.
Go toTop